ArticlePharmacoEconomics - open2024

Cost-Utility Analysis of Adjuvant Olaparib for Germline BRCA1/2-Mutated, High-Risk HER2-Negative Early Breast Cancer in Spain.

Sergio Cedillo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.